Clinical trials: Depression / Major Depressive Disorder
Major Depressive Disorder With Mixed Features
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
- Trial name
- RESOLVE 1 (NCT01421134)
- Testing
- Lurasidone
- Where
- 43 sites in United States, Russia and 3 more
- Volunteers
- 211 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder, Major
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing…
- Trial name
- NCT03185819
- Testing
- Midazolam, Esketamine
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 147 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Episode, Bipolar 1 Depression
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
A clinical study to test the effectiveness of an investigational drug to treat people that have major depressive episodes when they have Bipolar 1 Depression
- Trial name
- NCT03543410
- Testing
- SEP-4199 200 mg, SEP-4199 400 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 344 people
- Sponsor
- Sumitomo Pharma America, Inc.
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.
- Trial name
- NCT00824291
- Testing
- desvenlafaxine succinate sustained release, Genotyping
- Volunteers
- 437 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Alcohol Use Disorder
Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind…
- Trial name
- NCT02461927
- Testing
- Ketamine + Naltrexone
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder
The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
- Trial name
- TRD-2 (NCT00955955)
- Testing
- 6(S)-5-MTHF(Deplin)
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- George I. Papakostas
Adjunctive Treatment of Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with…
- Trial name
- NCT03018340
- Testing
- Pimavanserin
- Where
- 36 sites in United States
- Volunteers
- 207 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Depression, Major Depressive Episode
Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults
To evaluate the feasibility, tolerability and efficacy of Magnetic Seizure Therapy (MST) in elderly patients with a major depressive episode, who are randomly assigned to receive an acute course of MST or ECT.
- Conditions
- Depression, Major Depressive Episode, Bipolar Disorder
- Trial name
- MSTvsEST (NCT01869374)
- Testing
- MagVenture MagPro MST, RUL ECT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Generalized Anxiety Disorder
Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
The primary objective is to test the hypothesis that quetiapine XR (Extended Release) monotherapy or adjunctive therapy to antidepressant is superior to placebo monotherapy or placebo adjunctive therapy to antidepressant(s) in…
- Trial name
- MDD/GAD (NCT00868374)
- Testing
- Quetiapine XR
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Keming Gao
Post Traumatic Stress Disorder, Major Depressive Disorder
Primary-Care Based Mindfulness Intervention
The purpose of this study is to pilot a primary-care based mindfulness intervention for chronically traumatized African Americans screening positive for posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) in…
- Trial name
- NCT03922581
- Testing
- Mindfulness-Based Cognitive Therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Emory University
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Schizophrenia, Major Depression
Behavior During Experimentally Induced Pain
Numerous factors can influence the processing of pain message: the affective or emotional, the sensorial and the cognitive components.
- Trial name
- NCT01594528
- Testing
- pain tests
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Major Depressive Disorder
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
- Trial name
- NCT00854100
- Testing
- Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
- Where
- 41 sites in United States
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories
Depression, Postpartum
Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset
The purpose of this study is to evaluate the safety and effectiveness of acute NeuroStar TMS therapy in women who have postpartum depression.
- Trial name
- NCT01842542
- Testing
- NeuroStar Transcranial Magnetic Stimulation (TMS)
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Neuronetics
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
- Trial name
- NCT00849693
- Testing
- fluoxetine, duloxetine
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC